• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Funding Roundup

Titan Pharmaceuticals lands $10m debt facility

July 31, 2017 By Sarah Faulkner

Titan Pharmaceuticals

Titan Pharmaceuticals (NSDQ:TTNP) said last week that it inked a $10 million venture loan and security deal with Horizon Technology Finance Corp. The first $7 million tranche was triggered after the groups inked a deal, Titan reported, and a second option of $3 million is available to the California-based company until March 31, 2018, contingent upon […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Implants, Pharmaceuticals, Wall Street Beat Tagged With: Titan Pharmaceuticals

Kala nabs $104m in IPO

July 26, 2017 By Sarah Faulkner

Kala Pharmaceuticals

Kala Pharmaceuticals (NSDQ:KALA) said today that it closed its initial public offering of 6.9 million shares of common stock. The Waltham, Mass.-based company priced its public offering at $15.00 per share, granting underwriters an option to buy up to 900,000 additional shares. The exercise of this option brought the proceeds of its IPO up from $90 […]

Filed Under: Featured, Funding Roundup, Initial Public Offering (IPO), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Kala Pharmaceuticals

Lilly tops Q2 earnings, revenue estimates

July 25, 2017 By Sarah Faulkner

Eli Lilly

Shares in Eli Lilly (NYSE:LLY) fell today even though the drugmaker beat expectations on Wall Street with its second quarter results. The Indianapolis-based company posted profits of $1.01 billion, or 95¢ per share, on sales of $5.82 billion for the 3 months ended June 30, for bottom-line growth of 35% on sales growth of 8% compared […]

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

Sebacia raises $36m for microparticle acne treatment

July 25, 2017 By Sarah Faulkner

Sebacia

Privately-held Sebacia Inc. said today that it closed a $20 million Series D financing round, led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund. New investors, including Salem Partners, also joined the round. The Duluth, Ga.-based company also said it closed a $16 million debt facility with Hercules […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: sebacia

Brainstorm Cell Therapeutics wins $16m grant for pivotal NurOwn ALS study

July 21, 2017 By Fink Densford

BrainStorm Cell Therapeutics

Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis. Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Funding Roundup, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

Kala Pharmaceuticals prices $90m IPO

July 20, 2017 By Sarah Faulkner

Kala Pharmaceuticals

Kala Pharmaceuticals (NSDQ:KALA) today priced its initial public offering of 6 million shares of common stock at $15.00 apiece. The IPO is slated to bring in nearly $90 million for the Waltham, Mass.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy up to 900,000 additional shares […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO), Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Kala Pharmaceuticals

Inovio prices $75m public offering

July 20, 2017 By Sarah Faulkner

Inovio Pharmaceuticals

Inovio Pharmaceuticals (NSDQ:INO) said today that it priced its underwritten public offering of 12.5 million shares of common stock at $6.00 apiece. The offering is expected to bring in nearly $75 million for the Plymouth Meeting, Penn.-based company. The offering, which is expected to close on July 25, includes a 30-day option for underwriters to buy […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Wall Street Beat, Women's Health Tagged With: Inovio Pharmaceuticals

Inovio looks to raise $75m in public offering

July 19, 2017 By Sarah Faulkner

Inovio Pharmaceuticals

Inovio Pharmaceuticals (NSDQ:INO) said yesterday that it is launching an underwritten public offering to sell $75 million shares of common stock. The Plymouth Meeting, Penn.-based company said it plans to grant underwriters an option to buy up to $11.3 million additional shares of common stock. Inovio is slated to use its newly-acquired funds to support general […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy, Oncology, Wall Street Beat, Women's Health Tagged With: Inovio Pharmaceuticals

CDC gives $12m to states to fight opioid epidemic

July 18, 2017 By Sarah Faulkner

CDC

The Centers for Disease Control and Prevention said today that it plans to award more than $12 million this week to 23 states and the District of Columbia to support their efforts in tackling the opioid overdose epidemic. The funding comes from the fiscal year 2017 omnibus appropriations bill that became law in May. States […]

Filed Under: Featured, Funding Roundup, Pain Management, Pharmaceuticals, Policy Tagged With: Centers for Disease Control & Prevention

Provention Bio evaluates vaccine to prevent onset of T1D

July 18, 2017 By Sarah Faulkner

Provention Bio

Provention Bio said today that it licensed an enterovirus vaccine platform that it plans to evaluate as a way to prevent the onset of Type I diabetes by vaccinating against infection by a coxsackievirus B pathogen. Previous work has shown that CVB infection could be responsible for 50% of Type I diabetes cases worldwide, according […]

Filed Under: Clinical Trials, Diabetes, Featured, Funding Roundup, Pharmaceuticals Tagged With: Juvenile Diabetes Research Foundation (JDRF), proventionbio

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Interim pages omitted …
  • Page 47
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS